Figure 3. Determination of the cytotoxic effects of bevacizumab, anti-CTGF antibody and bevacizumab/anti-CTGF on human RPE cells. Cell
death ELISA assay was performed as described in methods, seeking for cytotoxic effects of the drugs. RPE cells treated by
0.25, 0.5 and 0.8 mg/ml of bevacizumab or 10 µg/ml of anti-CTGF or both of bevacizumab (0.8 mg/ml)/anti-CTGF (10 µg/ml). After
48 hours cultures were harvested and subjected to cell death assay according to the manufacturer’s instructions. Results indicated
that none of bevacizumab examined concentrations or anti-CTGF or simultaneous application of bevacizumab (0.8 mg/ml)/anti-CTGF
(10 µg/ml) did not impose cytotoxic effects on treated cultures when compared to the positive control that provided by the
kit. Each column shows comparison of specified treated culture with positive control (% of control) and each bar represents
the mean ± standard deviation (SD) of at least three independent experiments performed in triplicate. *p<0.05.